| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology |
Recent Updates
Recently added Catalysts
STERIS plc (Ireland)$218.4
+4.33 (+2.02%)
Market Cap
21.24 B
EPS
7.97
P/E Ratio
27.3 $
Value Trade
180.00 M
SEC Financials
Q1 2026Dilution Risk
Revenue
5.94 B
R&D Expenses
112.90 M
Operating CF
1.34 B
Total Assets
10.74 B
Total Liabilities
3.54 B
Equity
7.18 B
D/E Ratio
12,345
0.54 %
Week
-2.26 %
1 Month
-14.12 %
3 Month
-15.77 %
6 Month
13.59 %
5 Year
11,848.69 %
All Time
Cash Data
Cash Position
439.60 M
Monthly Burn
-
Runway
12,345 mo
Burn Trend
StableSEC Filing
May 29, 2026
Overview
Volume
715.48 K
52 Week Range
195.14 - 269.44
% held by Insiders
0.34 %
% held by Institutions
98.97 %
Enterprise Value
22.73 B
Total Shares
98.09 M
Short %
2.51 %
Float Shares
97.80 M
Company Description
locked
Upcoming Catalyst
Past FDA Catalysts & PDUFA Decisions
| Date | Drug | Catalyst | Stage | Outcome | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|---|
— | Example Drug | Phase 3 data readout | Phase 3 | — | – | 0% | 0% |
— | Example Drug | Phase 3 data readout | Phase 3 | — | – | 0% | 0% |
— | Example Drug | Phase 3 data readout | Phase 3 | — | – | 0% | 0% |
Drug Pipeline Intelligence
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | The study met its primary endpoint demonstrating statistically significant improvement. Read More | Phase 3 Study Results Announcement | |
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | The study met its primary endpoint demonstrating statistically significant improvement. Read More | Phase 3 Study Results Announcement | |
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | The study met its primary endpoint demonstrating statistically significant improvement. Read More | Phase 3 Study Results Announcement |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in STE
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
STE Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
| 2026-08-21 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
| 2026-08-21 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
| 2026-08-21 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
STE▲ +2%today
STERIS to Host a Conference Call for Fiscal 2027 First Quarter on August 6, 2026
STERIS plc will host a conference call on August 6, 2026, to discuss its fiscal 2027 first quarter results. The call will be accessible via phone and online, with a press release detailing financial results issued the day before. A replay will also be available for those unable to attend live.
Read more →STESTERIS Announces Financial Results for Fiscal 2026 Fourth Quarter and Full Year
STERIS plc reported a strong financial performance for fiscal 2026, with total revenue from continuing operations increasing by 9% to $5.9 billion. The company also announced a new $1 billion share repurchase program, reflecting confidence in its growth. Despite challenges such as tariffs and inflation affecting operating income, adjusted EPS rose to $10.17. Looking ahead, STERIS expects continued revenue growth in fiscal 2027.
Read more →STESTERIS Appoints Pierre Boulud to Board of Directors
STERIS plc has appointed Pierre Boulud to its Board of Directors effective May 5, 2026. Boulud, currently CEO of bioMérieux, brings significant leadership experience and a strong background in the healthcare sector. His appointment is seen as a strategic move to enhance STERIS's operational expertise and global perspective.
Read more →STESTERIS Announces Dividend of $0.63 per share
STERIS plc has declared a quarterly dividend of $0.63 per share, which will be paid on June 26, 2026, to shareholders registered by June 8, 2026. This decision reflects the company's ongoing commitment to providing shareholder value. The announcement supports STERIS's position as a leader in the healthcare industry, focusing on infection prevention. The company also reminded that they may face various risks related to operational and market conditions.
Read more →STESTERIS to Host a Conference Call for Fiscal 2026 Fourth Quarter and Full Year Results on May 12, 2026
STERIS plc will hold a conference call on May 12, 2026, to discuss its fiscal 2026 fourth quarter and full year results. The call is scheduled for 9:00 a.m. ET and will be accessible via phone and online. A press release with financial details will be issued after market close on May 11, 2026.
Read more →STE▼ -7.7%on this news
STERIS Announces Financial Results for Fiscal 2026 Third Quarter
STERIS plc reported a 9% increase in total revenue for its fiscal 2026 third quarter, reaching $1.5 billion. The company also saw a rise in adjusted net income to $249.4 million, driven by strong execution and a diversified portfolio. However, the outlook includes a negative impact from tariffs, estimated to reduce profits. The company maintains its revenue growth expectations for the fiscal year.
Read more →STESTERIS Announces Dividend of $0.63 per share - January 28, 2026
STERIS plc has announced a quarterly dividend of $0.63 per share, payable on March 19, 2026, to shareholders recorded by February 17, 2026. This decision highlights the company's ongoing commitment to providing value to its investors while continuing to focus on patient care and infection prevention. Additional tax information regarding the dividend is available on STERIS's investor relations website.
Read more →STESTERIS to Host a Conference Call for Fiscal 2026 Third Quarter Results on February 5, 2026
STERIS plc has announced a conference call scheduled for February 5, 2026, to discuss its fiscal 2026 third quarter results. The call will be accessible via phone and online, with a press release detailing financial results to be issued the day prior. A replay will also be available for those who cannot attend the live session.
Read more →STE▲ +6.9%on this news
STERIS Announces Financial Results for Fiscal 2026 Second Quarter
STERIS plc reported a 10% increase in total revenue for the second quarter of fiscal 2026, reaching $1.5 billion. Net income also rose to $191.9 million, leading to an improved outlook for the fiscal year. Despite challenges like tariffs and inflation, the company experienced growth across its healthcare and life sciences segments.
Read more →STESTERIS to Host a Conference Call for Fiscal 2026 Second Quarter Results on November 6, 2025
STERIS plc will host a conference call on November 6, 2025, to discuss its fiscal 2026 second quarter results. The call will be accessible via phone and online, with a press release detailing the financial results to be issued the day prior. A replay will also be available for those unable to attend live.
Read more →STE▲ +6.8%on this news
STERIS Announces Chief Financial Officer Transition
STERIS plc announced the transition of its Chief Financial Officer from Michael J. Tokich to Karen L. Burton, effective August 18, 2025. Tokich, who has served as CFO for 17 years, will become a Senior Financial Advisor. Burton, currently the Chief Accounting Officer, has been with STERIS for two decades and is expected to ensure a seamless transition.
Read more →STESTERIS Announces Financial Results for Fiscal 2026 First Quarter Total revenue from continuing operations increased 9% constant currency organic revenue grew 8% As reported EPS from continuing operations increased to $1.
STERIS plc reported a strong financial performance for the first quarter of fiscal 2026, with total revenue from continuing operations increasing by 9% to $1.4 billion. Adjusted EPS rose to $2.34, indicating improved profitability. The company has revised its revenue growth outlook for the fiscal year to 8-9%, due to favorable foreign currency conditions. However, ongoing tariff impacts and rising healthcare costs may pose challenges to profit margins.
Read more →STESTERIS Raises Dividend to $0.63 per share
STERIS plc has announced an increase in its quarterly dividend to $0.63 per share, marking the 20th consecutive year of dividend growth. The dividend will be payable on September 26, 2025, to shareholders recorded by September 4, 2025. This increase reflects the company's ongoing commitment to providing value to its shareholders.
Read more →STESTERIS to Host a Conference Call for Fiscal 2026 First Quarter Results on August 7, 2025
STERIS plc has announced a conference call scheduled for August 7, 2025, to discuss its fiscal 2026 first quarter results. Interested parties can access the call through various methods, including a live stream and phone dial-in options. A detailed press release with financial results will be available following the market close on August 6. A replay of the call will also be provided for those unable to attend live.
Read more →STESTERIS Announces Financial Results for Fiscal 2025 Fourth Quarter and Full Year Full year fiscal 2025 revenue from continuing operations increased 6% constant currency organic revenue growth was 6% Full year fiscal 2025
STERIS plc announced its financial results for the fourth quarter and full year of fiscal 2025, revealing a revenue increase of 6% from continuing operations to $5.5 billion. The company experienced a record fiscal year, with adjusted earnings per diluted share rising to $9.22. However, the Life Sciences segment saw a revenue drop of 7% due to the divestiture of a business segment. Looking forward, the company projects a 6-7% revenue increase and a slight rise in adjusted earnings for fiscal 2026.
Read more →STESTERIS Declares Dividend of $0.57 per share
STERIS plc has announced a quarterly interim dividend of $0.57 per share, payable on June 26, 2025, to shareholders recorded by June 10, 2025. This move underscores the company's ongoing commitment to shareholder value. STERIS is recognized for its role in enhancing patient care and infection prevention globally.
Read more →STESTERIS to Host a Conference Call for Fiscal 2025 Fourth Quarter and Full Year Financial Results on May 15, 2025
STERIS plc plans to hold a conference call on May 15, 2025, to review its fiscal 2025 fourth quarter and full year financial results. The call is scheduled to start at 9:00 a.m. ET and will be accessible via phone or live online. Financial results will be made available in a press release following the market close on May 14, 2025. A replay of the conference call will also be offered for those who cannot attend live.
Read more →STESTERIS Announces Financial Results for Fiscal 2025 Third Quarter Total revenue from continuing operations increased 6% constant currency organic revenue grew 6% As reported EPS from continuing operations increased to $1.
STERIS plc announced its financial results for the third quarter of fiscal 2025, reporting a 6% increase in total revenue from continuing operations, reaching $1.4 billion. Net income rose to $173.6 million, and adjusted earnings per share (EPS) improved to $2.32. However, the company updated its fiscal outlook, reducing revenue growth projections due to unfavorable foreign currency rates and lower capital equipment sales. Despite this, the overall financial performance for the first nine months shows improvement in cash flow and operating income.
Read more →STESTERIS to Host a Conference Call for Fiscal 2025 Third Quarter Financial Results on February 6, 2025
STERIS plc has announced that it will host a conference call to discuss its fiscal 2025 third quarter financial results on February 6, 2025. The call will take place at 9:00 a.m. ET and will be accessible via phone or online. A press release detailing the financial results will be issued on February 5, after the market closes, allowing investors and stakeholders to gain insights into the company's performance.
Read more →STESTERIS Announces Outcome of Ethylene Oxide Trial
STERIS plc announced that the jury trial involving its subsidiary Isomedix Operations, Inc. resulted in a mistrial. The case pertains to claims of personal injury linked to ethylene oxide emissions from a sterilization facility in Illinois. The mistrial was declared at the plaintiff's request after the jury count fell below twelve. Isomedix plans to vigorously defend itself in the re-trial scheduled for a later date, emphasizing their commitment to high environmental standards.
Read more →STESTERIS Announces Financial Results for Fiscal 2025 Second Quarter Total revenue from continuing operations increased 7% constant currency organic revenue grew 7% As reported EPS from continuing operations increased to $1
STERIS plc has reported its financial results for the second quarter of fiscal 2025, showing a total revenue increase of 7% year-over-year, reaching $1.3 billion. The company's net income rose to $150.2 million per share, compared to $119.8 million in the same quarter of the previous year, with adjusted EPS increasing to $2.14. Growth was particularly strong in healthcare services and sterilization technologies, while the company reiterated its revenue and earnings outlook for the full fiscal year. Challenges were noted in capital equipment and life sciences segments due to recent divestitures and increased costs.
Read more →STESTERIS to Host a Conference Call for Fiscal 2025 Second Quarter Financial Results on November 7, 2024
STERIS plc announced it will host a conference call on November 7, 2024, to discuss its fiscal 2025 second quarter financial results. The call will be accessible via the company's website and through specific phone numbers for international listeners. A press release detailing the financial results is expected to be issued after market close on November 6, 2024. This initiative reflects STERIS's commitment to keeping investors informed about its performance and strategic direction.
Read more →STESTERIS to Present at the Morgan Stanley Healthcare Conference
STERIS plc announced its participation in the Morgan Stanley Healthcare Conference, scheduled for September 4, 2024, where CEO Dan Carestio will deliver a presentation. The event will be accessible via a live webcast and replay on the company's investor relations website. STERIS is acknowledged as a global leader in products and services aimed at infection prevention in healthcare settings, emphasizing its commitment to enhancing patient safety.
Read more →STESTERIS Announces Financial Results for Fiscal 2025 First Quarter Total revenue from continuing operations increased 8% constant currency organic revenue grew 6% As reported EPS from continuing operations increased to $1.
STERIS plc announced its financial results for the first quarter of fiscal 2025, revealing a total revenue increase of 8% to $1.3 billion. The adjusted EPS rose to $2.03, while healthcare revenue experienced a notable 10% growth. However, the Life Sciences segment reported a 2% decrease in revenue attributed to a recent divestiture. Despite a slight decline in free cash flow, the company reiterated its fiscal 2025 outlook, anticipating continued growth in revenue and adjusted earnings.
Read more →STESTERIS Raises Dividend to $0.57 per share
STERIS plc announced an increase in its quarterly interim dividend to $0.57 per share, marking a $0.05 rise. This increase represents the company's 19th consecutive year of dividend growth. The dividend is scheduled for payment on September 20, 2024, to shareholders on record as of September 5, 2024. The company's focus on innovative healthcare and life sciences products continues to support its milestones in financial returns to investors.
Read more →STESTERIS to Host a Conference Call for Fiscal 2025 First Quarter Financial Results on August 7, 2024
STERIS plc has announced that it will host a conference call on August 7, 2024, to discuss its fiscal 2025 first quarter financial results. The call is expected to provide insights into the company's performance and future direction. A press release detailing the financial results will be issued prior to the call, enhancing transparency for investors. STERIS continues to prioritize its mission of supporting patient care and infection prevention through innovative products and services.
Read more →STESTERIS Announces Financial Results for Fiscal 2024 Fourth Quarter and Full Year Total fiscal 2024 revenue increase 12% to $5.5 billion Total fiscal 2024 U.S. GAAP earnings per diluted share of $3.81 adjusted earnings per
STERIS plc announced its financial results for the fiscal year 2024, reporting a revenue increase of 12% to $5.5 billion. While the company experienced a net loss of $1.4 million in the fourth quarter, adjusted earnings per diluted share rose to $2.58. The firm also announced a targeted restructuring plan, including a divestiture of the Dental segment, aimed at enhancing future growth. Despite some financial setbacks, management is optimistic about continued revenue growth in fiscal 2025, projecting increases of 6.5-7.5%.
Read more →STESTERIS Announces Dividend of $0.52 per share
STERIS plc has announced a quarterly interim dividend of $0.52 per share, which will be distributed on June 26, 2024, to shareholders of record as of June 12, 2024. This reflects the company's focus on returning value to its shareholders and highlights its position as a key player in healthcare and infection prevention. The announcement signifies stability and commitment to ongoing shareholder returns amidst evolving market conditions.
Read more →STESTERIS to Host a Conference Call for Fiscal 2024 Fourth Quarter and Full Year Financial Results on May 9, 2024
STERIS plc announced it will host a conference call on May 9, 2024, at 9:00 a.m. ET to discuss its fiscal 2024 fourth quarter and full year financial results. The conference call will be accessible both via a live stream on the company's investor relations website and through a dedicated phone line. A press release detailing the financial results is set to be released after the market closes on May 8, 2024. The event signifies STERIS's commitment to transparency and engagement with investors and analysts.
Read more →STESTERIS to Sell Dental Segment to an affiliate of Peak Rock Capital Transaction expected to close in STERIS s first quarter of fiscal 2025 Divestiture allows STERIS to focus on Customers within core markets Proceeds prima
STERIS plc has announced its decision to divest its Dental segment to Peak Rock Capital for $787.5 million, aiming to recalibrate its focus on core markets. The transaction is scheduled to close in the first quarter of fiscal 2025 and will be reported as discontinued operations for the current fiscal year. Proceeds from the sale will primarily be used to repay debt, potentially improving STERIS's financial footing by reducing interest expenses. An additional earnout of up to $12.5 million is possible, contingent on meeting revenue targets for the Dental segment in fiscal 2025.
Read more →STESTERIS Announces Financial Results for Fiscal 2024 Third Quarter Third quarter revenue increases 15% as reported 10% constant currency organic As reported diluted earnings per share increased to $1.42 adjusted earnings p
STERIS plc announced its financial results for the third quarter of fiscal 2024, indicating a revenue increase of 15% to $1.40 billion. The Healthcare segment experienced significant growth, contributing to an upgraded fiscal outlook. Adjusted earnings per share rose to $2.22, reflecting improved operational performance. However, the company faced challenges in its Dental segment with a revenue decline and reducing demand from certain customer sectors. Overall, the financial performance signals strong momentum, particularly in Healthcare.
Read more →STESTERIS to Host a Conference Call for Fiscal 2024 Third Quarter Financial Results on February 8, 2024
STERIS plc announced it will host a conference call on February 8, 2024, to discuss its fiscal 2024 third quarter financial results. The call will be accessible via live stream or phone, with a press release detailing financial outcomes released after market close on February 7. This move exemplifies STERIS's approach to maintaining clear communication with investors regarding its performance and future outlook.
Read more →STESTERIS Announces Financial Results for Fiscal 2024 Second Quarter Second quarter revenue growth of 12% as reported and 8% constant currency organic As reported diluted earnings per share increased to $1.16 adjusted earni
STERIS plc has reported financial results for its fiscal 2024 second quarter, revealing a 12% increase in revenue to $1.34 billion. The company's adjusted earnings per share rose to $2.03, and their Healthcare segment saw a significant 19% revenue growth, driven by increased sales in capital equipment and consumables. However, the Dental segment experienced a decline in revenue by 5%, and the Applied Sterilization Technologies segment faced challenges with capital equipment revenue. The company maintains its optimistic outlook for fiscal 2024, expecting continued revenue growth.
Read more →STESTERIS to Host a Conference Call for Fiscal 2024 Second Quarter Financial Results on November 8, 2023
STERIS plc plans to host a conference call on November 8, 2023, to discuss its fiscal 2024 second quarter financial results. A detailed press release will be issued after the U.S. market closes on November 7, 2023. The call will be accessible via a dedicated website and phone lines for both domestic and international participants, with replays available for those unable to join live. STERIS positions itself as a leader in the healthcare industry, focusing on infection prevention and innovative product offerings.
Read more →STESTERIS Completes the Acquisition of Surgical Instrumentation Assets from BD
STERIS plc has successfully completed the acquisition of surgical instrumentation, laparoscopic instrumentation, and sterilization container assets from Becton, Dickinson and Company (BD). The company's CEO Dan Carestio expressed optimism about the acquisition, highlighting its potential to enhance STERIS's product offerings within its Healthcare segment. Lazard acted as a financial advisor to STERIS while Thompson Hine LLP provided legal counsel for the transaction. The acquisition aims to strengthen STERIS's position in the market, although there are acknowledged risks associated with integration and regulatory compliance.
Read more →STESTERIS Announces Financial Results for Fiscal 2024 First Quarter First quarter revenue growth of 11% as reported and constant currency organic As reported diluted earnings per share increased to $1.25 adjusted earnings i
STERIS plc announced financial results for the first quarter of fiscal 2024, reporting an 11% revenue growth to $1.28 billion compared to the same period last year. The company experienced strong performance in its Healthcare segment, with a 17% increase in revenue. However, Life Sciences and Dental segments faced challenges, with revenue declines of 1% and 4%, respectively. STERIS also updated its fiscal outlook, projecting revenue increase driven by its acquisition of BD surgical instrumentation assets.
Read more →STESTERIS Raises Dividend to $0.52 per share
STERIS plc announced a quarterly interim dividend increase to $0.52 per share, marking a $0.05 rise. This dividend boost reflects the company's commitment to returning value to shareholders, evidenced by its 18 years of consecutive growth in dividends. The dividend will be payable on September 22, 2023, to shareholders recorded by September 6, 2023. This move indicates confidence in the company's ongoing financial performance and stability.
Read more →STESTERIS to Host a Conference Call for Fiscal 2024 First Quarter Financial Results on August 2, 2023
STERIS plc announced that it will host a conference call on August 2, 2023, to discuss its fiscal 2024 first quarter financial results. Interested parties can listen to the call live or access a replay afterward. A press release detailing financial results will be issued after the markets close on August 1, 2023. The company emphasizes its role in supporting patient care and infection prevention through innovative products and services.
Read more →STESTERIS Expands Healthcare Products Offering with Acquisition of Surgical Instrumentation Assets from Becton, Dickinson and Company for $540 million A natural extension for STERIS in the operating room and sterile process
STERIS plc has announced a definitive agreement to acquire surgical instrumentation, laparoscopic instrumentation, and sterilization container assets from Becton, Dickinson and Company for $540 million. This strategic acquisition is anticipated to enhance STERIS's Healthcare segment by integrating well-known brands such as V. Mueller, Snowden-Pencer, and Genesis. The transaction is expected to generate annual revenue of approximately $170 million and is projected to positively impact adjusted earnings in fiscal year 2024. The deal is set to close by September 30, 2023, pending regulatory approval.
Read more →STESTERIS Announces Financial Results for Fiscal 2023 Fourth Quarter and Full Year Fourth quarter as reported revenue increased 14% 16% constant currency organic revenue growth Fourth quarter as reported earnings per share
STERIS plc reported financial results for the fourth quarter and full year ended March 31, 2023. For Q4, the company achieved a revenue increase of 14% year-over-year, totaling $1.38 billion, driven largely by growth in its Healthcare segment. However, the full year net income declined significantly due to a major impairment charge. Looking ahead, STERIS anticipates a revenue increase of 7-8% for fiscal 2024, highlighting an optimistic outlook despite previous challenges.
Read more →STESTERIS Announces $500 million Share Repurchase Authorization and Declares $0.47 per share Dividend
DUBLIN, IRELAND, May 03, 2023 (GLOBE NEWSWIRE) -- STERIS plc (NYSE: STE) (“STERIS” or the “Company”) announced today that STERIS's Board of Directors has authorized a new share buyback program for the purchase of up to $500 million of the Company's ordinary shares. Shares may be
Read more →STESTERIS Appoints Esther M. Alegria, Ph.D. to Board of Directors DUBLIN, IRELAND
STERIS plc has appointed Esther M. Alegria, Ph.D., to its Board of Directors, effective immediately. Dr. Alegria, who has over three decades of experience in the biopharmaceuticals industry, is the Founder and CEO of APIE Therapeutics. Her prior roles include serving as President and Senior Executive Advisor at Catalyst Excel & Advance and Senior Vice President at Biogen, Inc. This appointment is expected to bolster STERIS's leadership with her extensive expertise in therapy development and biopharmaceutical operations.
Read more →STESTERIS to Host a Conference Call for Fiscal 2023 Fourth Quarter and Full Year Financial Results on May 11, 2023
DUBLIN, IRELAND, April 24, 2023 (GLOBE NEWSWIRE) -- STERIS plc (NYSE: STE) (“STERIS” or the “Company”) announced today that it will host a conference call to discuss its fiscal 2023 fourth quarter and full year financial results at 9:00 a.m. ET on May 11, 2023. The conference cal
Read more →STESTERIS Announces Financial Results for Fiscal 2023 Third Quarter As reported revenue increased 1% 7% constant currency organic revenue growth As reported earnings per share of $1.24 adjusted EPS of $2.02 Updated outlook
STERIS plc (NYSE: STE) reported its financial results for the third quarter of fiscal 2023, revealing a 1% increase in revenue to $1.22 billion. The company achieved a constant currency organic revenue growth of 7%, although net earnings decreased year-over-year. Challenges persisted with supply chain issues and reduced growth in bioprocessing volumes, impacting overall performance. Management revised its revenue growth forecast down to 6% and adjusted earnings per share expectations are set at $8.00 to $8.10 for the fiscal year.
Read more →STESTERIS Declares $0.47 per share Dividend
DUBLIN, IRELAND, Feb. 01, 2023 (GLOBE NEWSWIRE) -- STERIS plc (NYSE: STE) (“STERIS” or the “Company”) announced today that the Company will distribute a quarterly interim dividend of $0.47 per share. The dividend is payable March 23, 2023 to shareholders of record at the close o
Read more →STESTERIS to Host a Conference Call for Fiscal 2023 Third Quarter Financial Results on February 9, 2023
DUBLIN, IRELAND, Jan. 25, 2023 (GLOBE NEWSWIRE) -- STERIS plc (NYSE: STE) (“STERIS” or the “Company”) announced today that it will host a conference call to discuss its fiscal 2023 third quarter financial results at 10:00 a.m. ET on February 9, 2023. The conference call can be he
Read more →STESTERIS Announces Financial Results for Fiscal 2023 Second Quarter As reported revenue was flat 7% constant currency organic revenue growth As reported loss per share of ($3.15) adjusted EPS of $1.99 As reported loss incl
STERIS Announces Financial Results for Fiscal 2023 Second Quarter As reported revenue was flat 7% constant currency organic revenue growth As reported loss per share of ($3.15) adjusted EPS of $1.99 As reported loss includes an impairment charge of $490.6 million related to t
Read more →STESTERIS to Host a Conference Call for Fiscal 2023 Second Quarter Financial Results on November 10, 2022
DUBLIN, IRELAND, Oct. 25, 2022 (GLOBE NEWSWIRE) -- STERIS plc (NYSE: STE) (“STERIS” or the “Company”) announced today that it will host a conference call to discuss its fiscal 2023 second quarter financial results at 10:00 a.m. ET on November 10, 2022. The conference call can be
Read more →STESTERIS Announces Financial Results for Fiscal 2023 First Quarter First quarter revenue increases 19% as reported 6% constant currency organic As reported EPS of $1.10 adjusted EPS of $1.90 Updated outlook provided DUBLIN
STERIS Announces Financial Results for Fiscal 2023 First Quarter First quarter revenue increases 19% as reported 6% constant currency organic As reported EPS of $1.10 adjusted EPS of $1.90 Updated outlook provided DUBLIN, IRELAND - (August 2, 2022) - STERIS plc (NYSE STE) ("
Read more →STESTERIS Raises Dividend to $0.47 per share
DUBLIN, IRELAND, July 28, 2022 (GLOBE NEWSWIRE) -- STERIS plc (NYSE: STE) (“STERIS” or the “Company”) announced today that the Company will distribute a quarterly interim dividend of $0.47 per share. This represents a $0.04 increase in the dividend and the Company’s 17th consecu
Read more →STESTERIS to Host a Conference Call for Fiscal 2023 First Quarter Financial Results on August 3, 2022
DUBLIN, IRELAND, July 20, 2022 (GLOBE NEWSWIRE) -- STERIS plc (NYSE: STE) (“STERIS” or the “Company”) announced today that it will host a conference call to discuss its fiscal 2023 first quarter financial results at 10:00 a.m. ET on August 3, 2022. The conference call can be hear
Read more →STESTERIS Announces Financial Results for Fiscal 2022 Fourth Quarter and Full Year Fourth quarter revenue increases 39% as reported 11% constant currency organic As reported EPS of $0.52 adjusted EPS of $2.04 Company provid
STERIS Announces Financial Results for Fiscal 2022 Fourth Quarter and Full Year Fourth quarter revenue increases 39% as reported 11% constant currency organic As reported EPS of $0.52 adjusted EPS of $2.04 Company provides FY23 Outlook DUBLIN, IRELAND - (May 11, 2022) - STER
Read more →STESTERIS Declares $0.43 per share Dividend
DUBLIN, IRELAND , May 04, 2022 (GLOBE NEWSWIRE) -- STERIS plc (NYSE: STE) (“STERIS” or the “Company”) announced today that the Company will distribute a quarterly interim dividend of $0.43 per share. The dividend is payable June 28, 2022 to shareholders of record at the close of
Read more →STESTERIS to Host a Conference Call for Fiscal 2022 Fourth Quarter and Full Year Financial Results on May 12, 2022
DUBLIN, IRELAND, April 25, 2022 (GLOBE NEWSWIRE) -- STERIS plc (NYSE: STE) (“STERIS” or the “Company”) announced today that it will host a conference call to discuss its fiscal 2022 fourth quarter and full year financial results at 10:00 a.m. ET on May 12, 2022. The conference ca
Read more →STESTERIS Announces Financial Results for Fiscal 2022 Third Quarter Third quarter revenue increases 49% as reported 9% constant currency organic As reported EPS of $1.42 adjusted EPS of $2.12 Outlook for FY22 raised DUBLIN,
STERIS Announces Financial Results for Fiscal 2022 Third Quarter Third quarter revenue increases 49% as reported 9% constant currency organic As reported EPS of $1.42 adjusted EPS of $2.12 Outlook for FY22 raised DUBLIN, IRELAND - (February 8, 2022) - STERIS plc (NYSE STE) (
Read more →STESTERIS to Host a Conference Call for Fiscal 2022 Third Quarter Financial Results on February 9, 2022
DUBLIN, IRELAND, Jan. 25, 2022 (GLOBE NEWSWIRE) -- STERIS plc (NYSE: STE) (“STERIS” or the “Company”) announced today that it will host a conference call to discuss its fiscal 2022 third quarter financial results at 10:00 a.m. ET on February 9, 2022. The conference call can be he
Read more →STESTERIS Announces Financial Results for Fiscal 2022 Second Quarter Second quarter revenue increases 58% as reported 12% constant currency organic As reported EPS of $0.69 adjusted EPS of $1.99 Company reiterates fiscal 20
STERIS Announces Financial Results for Fiscal 2022 Second Quarter Second quarter revenue increases 58% as reported 12% constant currency organic As reported EPS of $0.69 adjusted EPS of $1.99 Company reiterates fiscal 2022 outlook DUBLIN, IRELAND - (November 2, 2021) - STERI
Read more →STESTERIS Announces Financial Results for Fiscal 2022 First Quarter First quarter revenue increases 45% as reported 21% constant currency organic Cantel Medical integration on track Company increases outlook and raises quar
STERIS Announces Financial Results for Fiscal 2022 First Quarter First quarter revenue increases 45% as reported 21% constant currency organic Cantel Medical integration on track Company increases outlook and raises quarterly dividend DUBLIN, IRELAND - (August 9, 2021) - STE
Read more →STEUNAUDITED PRO FORMA CONDENSED COMBINED FINANCIAL DATA The following unaudited condensed combined pro forma financial data ( pro forma financial data ) combines the historical consolidated financial positions and results
UNAUDITED PRO FORMA CONDENSED COMBINED FINANCIAL DATA The following unaudited condensed combined pro forma financial data ( pro forma financial data ) combines the historical consolidated financial positions and results of operations of STERIS plc ( STERIS ) and Cantel Medical
Read more →STESTERIS Announces Financial Results for Fiscal 2021 Fourth Quarter and Full Year Fourth quarter revenue increases 6% as reported full year increases 3% as reported Full year earnings per diluted share of $4.63 on a U.S. G
STERIS Announces Financial Results for Fiscal 2021 Fourth Quarter and Full Year Fourth quarter revenue increases 6% as reported full year increases 3% as reported Full year earnings per diluted share of $4.63 on a U.S. GAAP basis and $6.17 on an adjusted basis on effective tax
Read more →STESTERIS Announces Changes to Board of Directors David B. Lewis to retire at the Company s 2021 Annual Meeting of Shareholders Company appoints Paul E. Martin to Board DUBLIN, IRELAND (
STERIS Announces Changes to Board of Directors David B. Lewis to retire at the Company s 2021 Annual Meeting of Shareholders Company appoints Paul E. Martin to Board DUBLIN, IRELAND (May 11, 2021) STERIS plc (NYSE: STE) ( STERIS or the Company ) today announced changes to its
Read more →STESTERIS Announces Preliminary Financial Results for Fiscal 2021 Company expects to close the Cantel Medical acquisition by
STERIS Announces Preliminary Financial Results for Fiscal 2021 DUBLIN, IRELAND - (April 27, 2021) - STERIS plc (NYSE: STE) ("STERIS" or the "Company") today announced preliminary financial results for its fiscal 2021 year ending March 31, 2021. The Company expects to report tha
Read more →STESTERIS Announces Leadership Succession Plan Walt Rosebrough to step down as CEO at the upcoming Annual General Meeting Chief Operating Officer, Dan Carestio, to succeed as President and CEO DUBLIN, IRELAND - (
STERIS Announces Leadership Succession Plan DUBLIN, IRELAND - (February 3, 2021) - STERIS plc (NYSE: STE) ( STERIS or the Company ) today announced that Walt Rosebrough, President and CEO, has announced his intention to step down on July 29, 2021, in conjunction with the compan
Read more →STESTERIS Announces Financial Results for Fiscal 2021 Third Quarter Third quarter revenue increases 4% as reported 1% constant currency organic Third quarter earnings per diluted share increase to $1.33 on a U.S. GAAP basis
STERIS Announces Financial Results for Fiscal 2021 Third Quarter Third quarter revenue increases 4% as reported 1% constant currency organic Third quarter earnings per diluted share increase to $1.33 on a U.S. GAAP basis and $1.73 on an adjusted basis Increased free cash flow
Read more →STESTERIS Announces Definitive Agreement to Acquire Cantel Medical Complementary to STERIS's product and service portfolio, focused on infection prevention Extends STERIS's reach to Dental Customers $110 million in expected
STERIS Announces Definitive Agreement to Acquire Cantel Medical DUBLIN, IRELAND and LITTLE FALLS, N.J. - (January 12, 2021) - STERIS plc (NYSE: STE) ("STERIS" or the "Company") and Cantel Medical Corp (NYSE:CMD) ("Cantel") today announced that STERIS has signed a definitive agre
Read more →STEPrivileged and Confidential STERIS Completes Acquisition of Key Surgical DUBLIN, IRELAND - (
Privileged and Confidential STERIS Completes Acquisition of Key Surgical DUBLIN, IRELAND - (November 18, 2020) - STERIS plc (NYSE: STE) ( STERIS or the Company ) today announced that is has completed the previously announced acquisition of Key Surgical, a portfolio company of
Read more →STESTERIS Announces Financial Results for Fiscal 2021 Second Quarter Second quarter revenue increases 3% as reported 2% constant currency organic Second quarter earnings per diluted share increase to $1.23 on a U.S. GAAP ba
STERIS Announces Financial Results for Fiscal 2021 Second Quarter Second quarter revenue increases 3% as reported 2% constant currency organic Second quarter earnings per diluted share increase to $1.23 on a U.S. GAAP basis and $1.48 on an adjusted basis Increased cash flow d
Read more →STESTERIS Expands Healthcare Consumables Offering with Acquisition of Key Surgical for approximately $850 million Consumable product portfolio a natural extension for STERIS s Customers in sterile processing departments, op
STERIS Expands Healthcare Consumables Offering with Acquisition of Key Surgical for approximately $850 million DUBLIN, IRELAND - (October 6, 2020) - STERIS plc (NYSE: STE) ( STERIS or the Company ) today announced that the Company has signed a definitive agreement to purchase
Read more →STESTERIS Announces Financial Results for Fiscal 2021 First Quarter First quarter revenue declines low-single digits due to reduction in deferrable procedures First quarter net income grows low-single digits driven by margi
STERIS Announces Financial Results for Fiscal 2021 First Quarter DUBLIN, IRELAND - (August 3, 2020) - STERIS plc (NYSE: STE) ("STERIS" or the "Company") today announced financial results for its fiscal 2021 first quarter ended June 30, 2020. Revenue as reported for the quarter d
Read more →STESTERIS Announces Financial Results for Fiscal 2020 Fourth Quarter and Full Year Strong fourth quarter and full year revenue growth and profitability Company not providing guidance for fiscal 2021 at this time due to COVI
STERIS Announces Financial Results for Fiscal 2020 Fourth Quarter and Full Year DUBLIN, IRELAND - (May 13, 2020) - STERIS plc (NYSE: STE) ("STERIS" or the "Company") today announced financial results for its fiscal 2020 fourth quarter ended March 31, 2020. Revenue as reported fo
Read more →STESTERIS Announces Financial Results for Fiscal 2020 Third Quarter Third quarter revenue grows 11% as reported, 12% constant currency organic EPS as reported increases to $1.23 , adjusted EPS increases to $1.45 Outlook upd
STERIS Announces Financial Results for Fiscal 2020 Third Quarter DUBLIN, IRELAND - (February 10, 2020) - STERIS plc (NYSE: STE) ("STERIS" or the "Company") today announced financial results for its fiscal 2020 third quarter ended December 31, 2019. Revenue as reported for the qu
Read more →STESTERIS Announces Financial Results for Fiscal 2020 Second Quarter Second quarter revenue grows 9% as reported, 10% constant currency organic EPS as reported increases to $1.11 , adjusted EPS increases to $1.32 Outlook up
STERIS Announces Financial Results for Fiscal 2020 Second Quarter DUBLIN, IRELAND - (November 4, 2019) - STERIS plc (NYSE: STE) ("STERIS" or the "Company") today announced financial results for its fiscal 2020 second quarter ended September 30, 2019. Revenue as reported for the
Read more →STESTERIS Announces Financial Results for Fiscal 2020 First Quarter First quarter revenue grows 9% as reported, 10% constant currency organic revenue growth EPS as reported increases to $0.99 , adjusted EPS increases to $1.
STERIS Announces Financial Results for Fiscal 2020 First Quarter DUBLIN, IRELAND - (August 5, 2019) - STERIS plc (NYSE: STE) ("STERIS" or the "Company") today announced financial results for its fiscal 2020 first quarter ended June 30, 2019. Revenue as reported for the quarter i
Read more →STESTERIS Announces Financial Results for Fiscal 2019 Fourth Quarter and Full Year Strong fourth quarter revenue growth Fourth quarter earnings improve to $1.27 per diluted share as reported; adjusted earnings per diluted s
STERIS Announces Financial Results for Fiscal 2019 Fourth Quarter and Full Year DUBLIN, IRELAND - (May 13, 2019) - STERIS plc (NYSE: STE) ( STERIS or the Company ) today announced financial results for its fiscal 2019 fourth quarter ended March 31, 2019. Revenue as reported for
Read more →Competitive Position
How STE ranks across every disease it competes inCompetitive Position is a premium feature
See how STE ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial